<DOC>
	<DOC>NCT02819271</DOC>
	<brief_summary>This study is designed to assess a safe dosage of the drug CXL-1427 (BMS-986231) in healthy volunteers.</brief_summary>
	<brief_title>A First-in-Human Study of the Safety of Single Continuous Intravenous (IV) Infusions of CXL-1427 for up to 48 Hours in Healthy Volunteers</brief_title>
	<detailed_description />
	<mesh_term>Heart Failure</mesh_term>
	<criteria>No evidence of any acute or chronic health disorder Not have taken any prescription medication within 15 days of study entry Not have taken any overthecounter medication or herbal/vitamin supplement within 3 days of study entry Not have not have any dietary restrictions Have a body mass index (BMI) of ≥18 to ≤34 Weigh at least 50kg (110 pounds) Be a current or recent (within 6 months of the Screening Visit) smoker or user of any nicotinecontaining product Have a history of symptomatic hypotension, orthostatic hypotension or syncope Have a history of headaches or other symptoms attributable to caffeine withdrawal Have a history of any bleeding diathesis Have a positive serology screen for HIV antibody, hepatitis B surface antigen or hepatitis C antibody at screening Other protocol defined inclusion/exclusion criteria could apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>August 2016</verification_date>
</DOC>